The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | How can BCMA be used as a target for mutiple myeloma treatment?
Sagar Lonial, MD, FCAP, from the Winship Cancer Institute, Atlanta, GA, explores the question of what is the best way to use BCMA (B-cell maturation antigen) as a target for multiple myeloma treatment. He explains that they are hopeful that targeting BCMA will have a great impact on myeloma, just as CD38 has had. Previous studies have seen data on a BCMA drug conjugate. There also is emerging data on BCMA as a bispecific and there are now two or three groups who have published data on BCMA for CAR-T cells. However, Dr Lonial explains that although there is currently not enough data, he is hopeful that within the next few years, the best approach will be known.
